SNPMiner Trials by Shray Alag


SNPMiner SNPMiner Trials (Home Page)


Report for Clinical Trial NCT00130078

Developed by Shray Alag, 2020.
SNP Clinical Trial Gene

Randomized Controlled Trial of SAVVY and HIV in Nigeria

Heterosexual contact is now the primary route of transmission for HIV worldwide. This study is a phase 3 trial designed to determine the effectiveness and safety of the 1.0% C31G (SAVVY) vaginal gel for the prevention of male-to-female transmission of HIV among women at high risk.

NCT00130078 HIV Infections
MeSH:HIV Infections

1 Interventions

Name: 1.0% C31G SAVVY vaginal gel

Type: Drug


Primary Outcomes

Measure: Combined incidence of HIV-1 and HIV-2

Purpose: Prevention

Allocation: Randomized

Parallel Assignment


There is one SNP

SNPs


1 C31G

This study is a phase 3 trial designed to determine the effectiveness and safety of the 1.0% C31G (SAVVY) vaginal gel for the prevention of male-to-female transmission of HIV among women at high risk. --- C31G ---

This study is a phase 3 multi-center, fully-masked, randomized, placebo controlled trial designed to determine the effectiveness and safety of the 1.0% C31G (SAVVY) vaginal gel for the prevention of male-to-female transmission of HIV among women at high risk. --- C31G ---



HPO Nodes